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The SARS-coronavirus (SARS-CoV) is the etiological agent of severe acute respiratory syndrome (SARS). The SARS-CoV spike (S)
glycoprotein mediates membrane fusion events during virus entry and virus-induced cell-to-cell fusion. To delineate functional domains of
the SARS-CoV S glycoprotein, single point mutations, cluster-to-lysine and cluster-to-alanine mutations, as well as carboxyl-terminal
truncations were investigated in transient expression experiments. Mutagenesis of either the coiled-coil domain of the S glycoprotein amino
terminal heptad repeat, the predicted fusion peptide, or an adjacent but distinct region, severely compromised S-mediated cell-to-cell fusion,
while intracellular transport and cell-surface expression were not adversely affected. Surprisingly, a carboxyl-terminal truncation of 17 amino
acids substantially increased S glycoprotein-mediated cell-to-cell fusion suggesting that the terminal 17 amino acids regulated the S fusogenic
properties. In contrast, truncation of 26 or 39 amino acids eliminating either one or both of the two endodomain cysteine-rich motifs,
respectively, inhibited cell fusion in comparison to the wild-type S. The 17 and 26 amino-acid deletions did not adversely affect S cell-surface
expression, while the 39 amino-acid truncation inhibited S cell-surface expression suggesting that the membrane proximal cysteine-rich motif
plays an essential role in S cell-surface expression. Mutagenesis of the acidic amino-acid cluster in the carboxyl terminus of the S
glycoprotein as well as modification of a predicted phosphorylation site within the acidic cluster revealed that this amino-acid motif may play
a functional role in the retention of S at cell surfaces. This genetic analysis reveals that the SARS-CoV S glycoprotein contains extracellular
domains that regulate cell fusion as well as distinct endodomains that function in intracellular transport, cell-surface expression, and cell
fusion.
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mortality rates of the disease reached as high as 15% in
some age groups (Anand et al., 2003). The etiological agent
of the disease was found to be a novel coronavirus (SARS-
CoV), which was first isolated from infected individuals by
propagation of the virus on Vero E6 cells (Drosten et al.,
2003; Ksiazek et al., 2003; Peiris et al., 2003). Analysis of
the viral genome has demonstrated that the SARS-CoV is
phylogenetically divergent from the three known antigenic
groups of coronaviruses (Drosten et al., 2003; Ksiazek et al.,05) 215 – 230
C.M. Petit et al. / Virology 341 (2005) 215–2302162003). Analysis of the polymerase gene alone, however, has
indicated that the SARS-CoV may be an early off-shoot
from the group 2 coronaviruses (Snijder et al., 2003).
The coronaviruses are the largest of the enveloped RNA
viruses with a positive-stranded RNA genome of 28 to 32
kb (Holmes, 2003). Coronaviruses possess a wide host
range, capable of infecting mammalian and avian species.
All identified coronaviruses have a common group of
indispensable genes that encode nonstructural proteins
including the RNA replicase gene open reading frame
(ORF) 1ab and the structural proteins nucleocapsid (N),
membrane protein (M), envelope protein (E), and spike
glycoprotein (S), which are assembled into virus particles. A
hemagglutinin-esterase (HE) protein is also encoded by
some coronaviruses. Distributed among the major viral
genes are a series of ORFs that are specific to the different
coronavirus groups. Functions of the majority of these
ORFs have not been determined.
The SARS spike glycoprotein, a 1255-amino-acid type I
membrane glycoprotein (Rota et al., 2003), is the major
protein present in the viral membrane forming the typical
spike structure found on all coronavirions. The S glyco-
protein is primarily responsible for entry of all coronavi-
ruses into susceptible cells through binding to specific
receptors on cells and mediating subsequent virus-cell
fusion (Cavanagh, 1995). The S glycoprotein specified by
mouse hepatitis virus (MHV) is cleaved into S1 and S2
subunits, although cleavage is not necessarily required for
virus-cell fusion (Bos et al., 1997; Gombold et al., 1993;
Stauber et al., 1993). Similarly, the SARS-CoV S glyco-
protein seems to be cleaved into S1 and S2 subunits in Vero-
E6-infected cells (Wu et al., 2004), while it is not known
whether this cleavage affects S-mediated cell fusion. The
SARS-CoV receptor has been recently identified as the
angiotensin-converting enzyme 2 (ACE2) (Li et al., 2003).
Although the exact mechanism by which the SARS-CoV
enters the host cell has not been elucidated, it is most likely
similar to other coronaviruses. Upon receptor binding at the
cell membrane, the S glycoprotein is thought to undergo a
dramatic conformational change causing exposure of a
hydrophobic fusion peptide, which is subsequently inserted
into cellular membranes. This conformational change of the
S glycoprotein causes close apposition followed by fusion
of the viral and cellular membranes resulting in entry of the
virion nucleocapsids into cells (Eckert and Kim, 2001; Tsai
et al., 2003; Zelus et al., 2003). This series of S-mediated
virus entry events is similar to other class I virus fusion
proteins (Baker et al., 1999; Melikyan et al., 2000; Russell
et al., 2001).
Heptad repeat (HR) regions, a sequence motif character-
istic of coiled-coils, appear to be a common motif in many
viral and cellular fusion proteins (Skehel and Wiley, 1998).
These coiled-coil regions allow the protein to fold back
upon itself as a prerequisite step to initiating the membrane
fusion event. There are usually two HR regions: an N
terminal HR region adjacent to the fusion peptide and a C-terminal HR region close to the transmembrane region of
the protein. Within the HR segments, the first amino acid (a)
and fourth amino acid (d) are typically hydrophobic amino
acids that play a vital role in maintaining coiled-coil
interactions. Based on structural similarities, two classes
of viral fusion proteins have been established. Class I viral
fusion proteins contain two heptad repeat regions and an N-
terminal or N-proximal fusion peptide. Class II viral fusion
proteins lack heptad repeat regions and contain an internal
fusion peptide (Lescar et al., 2001). The MHV S glyco-
protein, which is similar to other coronavirus S glycopro-
teins, is a class I membrane protein that is transported to the
plasma membrane after being synthesized in the endoplas-
mic reticulum (Bosch et al., 2003). Typically, the ectodo-
mains of the S2 subunits of coronaviruses contain two
regions with a 4, 3 hydrophobic (heptad) repeat the first
being adjacent to the fusion peptide and the other being in
close proximity to the transmembrane region (de Groot
et al., 1987).
In the present study, we investigated the role of several
predicted structural and functional domains of the SARS
spike glycoprotein by introducing specific alterations within
selected S glycoprotein regions. The results show that the
SARS-CoV S glycoprotein conforms to the general struc-
ture and function relationships that have been elucidated for
other coronaviruses, most notably the MHV (Chang et al.,
2000; Ye et al., 2004). However, in contrast to the MHV
endodomain, the carboxyl terminus of the SARS-CoV S
glycoprotein contains multiple non-overlapping domains
that function in intracellular transport, cell-surface expres-
sion, and endocytosis as well as in S glycoprotein-mediated
cell-to-cell fusion.Results
Genetic analysis of S glycoprotein functional domains
To delineate domains of the S glycoprotein that function
in membrane fusion, intracellular transport, and cell-surface
expression, two types of mutations were introduced within
the S gene: (a) mutations were introduced within and
adjacent to the predicted amino terminal heptad repeat
(HR1) core and the predicted fusion peptide, which are
known to play important roles in membrane fusion (Bosch
et al., 2004; Bosch et al., 2003; Ingallinella et al., 2004;
Tripet et al., 2004); (b) mutations and carboxyl-terminal
truncations of the S glycoprotein were engineered to
delineate S cytoplasmic domains that function in glycopro-
tein synthesis, intracellular transport, and membrane fusion
(Fig. 1). Specifically, to investigate the amino-acid require-
ments of the HR1 of the SARS-CoV S glycoprotein, the a
and d amino-acid positions L(898) and N(901) were both
replaced by lysine residues in the cluster mutation CL2,
effectively collapsing the predicted a-helical structure at the
amino terminal terminus of the HR. This amino-acid
Fig. 1. Schematic diagram of the SARS-CoV S glycoprotein. (A) Graphical representation of the S glycoprotein showing the approximate location of the
cluster to lysine mutations CL1–CL5 relative to known and indicated functional domains. (B) Shown on the top of the diagram is a graphical representation of
the SARS-CoV S glycoprotein. The predicted fusion peptide and the HR1 region are enlarged below to show the sets of amino acids replaced by lysines in the
cluster mutations. The heptad repeat a and d positions are labeled above the corresponding amino acid. Amino acids changed to lysine are demarcated by
arrows with the name of that particular mutation shown in brackets. (C) Amino-acid sequences of the carboxyl termini of the truncation and acidic cluster
associated mutations. Cysteine clusters (CRM1 and CRM2) are denoted by underlined italicized text as well as a bracket encompassing their respective regions.
The charged cluster is bracketed over the region. Amino acids mutated to alanines for the CL6 and CL7 cluster mutations are in bold.
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formation of the HR1/HR2 core complex (Xu et al., 2004).
In addition, cluster-to-lysine mutations CL3 and CL4
replaced the a and d positions within the HR1 region (Fig.
1B). The CL5 cluster mutation was placed adjacent to the
HR1 region to investigate whether regions proximal to HR1
had any effect on S-mediated cell fusion. Similarly, the role
of the a and d positions within the predicted fusion peptide,
located immediately proximal to the N terminus of HR1,
was investigated by constructing the CL1 cluster mutation
(Fig. 1B).
It has been shown for other viral class I fusion proteins
that the carboxyl terminus plays a regulatory role in
membrane fusion (Bagai and Lamb, 1996; Sergel and
Morrison, 1995; Seth et al., 2003; Tong et al., 2002; Yao
and Compans, 1995). Specifically, for coronaviruses, the
MHV S glycoprotein endodomain has been shown to
contain charged-rich and cysteine-rich regions, which are
critical for fusion of infected cells (Bos et al., 1995; Chang
et al., 2000; Ye et al., 2004). The carboxyl-terminal portion
of the S glycoprotein contains a consensus acidic amino-
acid cluster with a motif that has been predicted by the
NetPhos 2.0 software to be phosphorylated (Blom et al.,
1999). To investigate the potential role of the acidic amino-
acid cluster in synthesis, transport, and cell fusion, serial
truncations of S were constructed. The acidic cluster was
specifically targeted by mutagenizing the predicted phos-
phorylation site embedded within the acidic cluster as well
as by replacing acidic residues of the acidic cluster with
alanine residues. In addition, carboxyl-terminal truncations
of 8, 17, 26, and 41 amino acids were engineered by
insertion of stop codons within the S glycoprotein gene. The
8 aa truncation (T1247) was designed to bring the predicted
charged cluster DEDDSE proximal to the carboxyl terminus
of the mutated S glycoprotein (Fig. 1C). Similarly, the 17 aa
truncation (T1238) was designed to delete the DEDDSE
acidic cluster. The SARS-CoV S glycoprotein endodomain
contains two cysteine residue clusters, a CCMTSCCSC
(CRM1) cluster immediately adjacent to the membrane and
a CSCGSCC (CRM2) downstream of the first cluster. To
address the role of these domains in S glycoprotein-
mediated cell-to-cell fusion, the 26 aa truncation (T1229)
was designed to delete the CRM2 domain, while the 41 aa
truncation (T1214) deleted both the CRM1 and CRM2
domains (Fig. 1C).
Effect of mutations on S synthesis
To investigate the effect of the different mutations on S
synthesis, western immunoblot analysis was used to detect
and visualize all of the constructed mutant glycoproteins as
well as the wild-type S (Fig. 2). Cellular lysates prepared
from transfected cells at 48 h post-transfection were electro-
phoretically separated by SDS-PAGE and the S glycoproteins
were detected via chemiluminescence using a monoclonal
antibody specific for the SARS-CoV S glycoprotein.Carbohydrate addition was shown to occur in at least four
different locations of the SARS-CoV S glycoprotein (Kro-
khin et al., 2003; Ying et al., 2004). Furthermore, transiently
expressed S glycoprotein in Vero E6 cells was proteolyti-
cally cleaved into S1 and S2 components (Wu et al., 2004).
The anti-S monoclonal antibody SW-111 detected a protein
species in cellular extracts from transfected cells, which
migrated with an apparent molecular mass of approximately
180 kDa, as reported previously (Song et al., 2004). All
mutated S glycoproteins produced similar S-related protein
species to that of the wild-type S indicating that none of the
engineered mutations adversely affect S synthesis and
intracellular processing (Fig. 2A). The SARS S glycoprotein
is known to form homotrimers in its native state (Song et al.,
2004). To investigate the effect of the mutations on S
oligomerization, cellular lysates from transfected cells were
electrophoretically separated without prior boiling of the
samples and in the absence of reducing agents (Song et al.,
2004). The different S species were detected via chemilu-
minescence using the monoclonal SW-111 to the SARS S
glycoprotein. An S protein species was detected that had an
approximate apparent molecular mass of 500 kDa, which
was consistent with previously published data (Song et al.,
2004) (Fig. 2B). Although levels of oligomer expression
seemed to vary slightly between mutant forms, all mutated S
glycoproteins produced similar species to the wild type,
indicating that none of the mutations blocked oligomeriza-
tion from occurring.
Ability of mutant S glycoproteins to be expressed on the cell
surface
To determine if the mutant S glycoproteins were
expressed on the surface of cells, immunohistochemical
analysis was used to label cell-surface-expressed S under
live cell conditions that restrict antibody binding to cell
surfaces. In addition, immunohistochemistry was used to
detect the total amount of S expressed in cells by fixing and
permeabilizing the cells prior to reaction with the antibody.
A recombinant S protein having the 3xFLAG added in-
frame to the carboxyl terminus of S was used as a negative
control, since it would not be stained by the live cell
reaction conditions (see Materials and methods). Both wild-
type versions of S having the 3xFLAG, either at the amino
or carboxyl terminus of S, caused similar amounts of fusion
(Fig. 3), which also was similar to that obtained with the
untagged wild-type S (not shown). The relative amounts of
cell-surface versus total cellular expression of S were
obtained through the use of an ELISA. A ratio between
the cell-surface localized S and total cellular S expression
was then calculated and normalized to the corresponding
ratio obtained with the wild-type S glycoprotein (see
Materials and methods) (Fig. 4). The CL1 (95%), CL2
(78%), CL3 (86%), CL4 (80%), CL5 (92%), CL6 (86%)
mutants as well as the T1229 (91%), T1238 (94%), and
T1247 (79%) truncations were expressed on the cellular
Fig. 2. Western blot analysis of the expressed mutant SARS-CoV S mutant glycoproteins. (A, B) Immunoblots of wild-type [3xFLAG So (WT)], cluster to
lysine, cluster to alanine, and carboxyl truncation mutant S glycoproteins probed with monoclonal anti-SARS S antiserum. ‘‘Cells only’’ represents a negative
control in which Vero cells with no protein transfected into them were probed with the monoclonal antibody to SARS S glycoprotein. (B) In order to detect
trimer formation more efficiently, the protein extracts of the mutants were neither boiled nor subject to treatment with beta mercaptoethanol.
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cell-surface expression of the wild-type protein. In contrast,
the 1214T mutant expressed 77% less S on cell surfaces in
comparison to the wild-type S (Fig. 4).
Effect of mutations on S-mediated cell-to-cell fusion
Transiently expressed wild-type S causes extensive cell-
to-cell fusion (syncytial formation), especially in the
presence of the SARS-CoV ACE2 receptor (Li et al.,
2003). To determine the ability of each mutant S glyco-
protein to cause cell-to-cell fusion and the formation of
syncytia, fused cells were labeled by immunohistochemistry
using the anti-FLAG antibody (Fig. 5). The extent of cell-to-
cell fusion caused by each mutant glycoprotein was
calculated by obtaining the average size of approximately
300 syncytia. The average syncytium size for each mutant
was then normalized to that found in wild-type S-transfected
cells (see Materials and methods). The CL1 (73%), CL2
(75%), CL3 (68%), CL4 (71%), CL5 (76%), CL6 (51%) as
well as the T1214 (86%) and T1247 (66%) mutants
inhibited the formation of syncytia by the percentages
indicated. The T1229 truncation and the cluster mutant CL7produced syncytia, which were on the average 22% and
15% smaller, respectively, than that of the wild-type S. In
contrast, the T1238 mutant produced on the average 43%
larger syncytia than that of the wild-type S (Fig. 5).
Comparison of the membrane fusion and cell-surface
expression results allowed the grouping of the different
mutant S phenotypes into four distinct groups (Table 1): (1) S
mutant forms in Group I (CL1–CL6 and T1247) resulted in
high levels of cell-surface expression (78–95% of the wild-
type S); however, the average size of syncytial formed by
these mutated S glycoproteins was reduced substantially in
comparison to the wild-type S (23–48% of the wild-type).
CL1 affects the predicted fusion peptide, CL2–CL4 affect the
HR1 domain, and CL5 affects a region downstream of the
HR1 domain. The CL6 mutation is located within the S
carboxyl-terminal acidic cluster. The T1247 mutation trun-
cates the S carboxyl terminus by 8 amino acids; (2) S mutant
forms in Group II produced high levels of S cell-surface
expression and an average size of syncytia slightly smaller
than that of the wild-type S. These mutations included CL7,
which modified the acidic cluster and the T1229 truncations
that deleted the cysteine-rich motif CRM2; (3) the single S
mutant in Group III, T1214, produced significantly less cell-
Fig. 3. Immunohistochemical detection of cell-surface and total expression of the SARS-CoV S wild-type and mutant proteins. Vero cells were transfected with
the wild-type SARS-CoVoptimized S [3xFLAG So (WT)] (F1, F2), CL1 (A1, A2), CL2 (B1, B2), CL3 (C1, C2), CL4 (D1, D2), CL5 (E1, E2), CL6 (L1, L2),
CL7 (M1, M2), T1214 (K1, K2), T1229 (J1, J2), T1238 (I1, I2), T1247(H1, H2) and a wild-type SARS-CoVoptimized S labeled with a 3xFLAG carboxyl tag
(G1, G2), which served as a negative control. At 48 h post-transfection, cells were immunohistochemically processed either under live conditions to show
surface expression (A2, B2, C2, D2, E2, F2, G2, H2, I2, J2, K2, L2, and M2) or fixed and permeabilized conditions to show total expression (A1, B1, C1, D1,
E1, F1, G1, H1, I1, J1, K1, L1, and M1).
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syncytia was substantially reduced in comparison to the wild-
type S; (4) the T1238 truncation in Group IV produced high
levels of cell-surface expression equivalent to that of the wild
type (94% of the wild-type S), while the average syncytium
size was 43% larger than that the syncytial produced by the
wild-type S (Table 1).Detection of the intracellular distribution of S mutant
glycoproteins via confocal microscopy
To visualize the intracellular distribution of S mutant
glycoproteins, cells were transfected with plasmids encod-
ing the wild-type or S mutants and examined by confocal
microscopy at 48 h post-transfection (Fig. 6). The wild-type
Fig. 4. Ratios of cell-surface to total cellular expression of mutant SARS-CoV S glycoproteins. Detection of cell-surface and total glycoprotein distribution was
determined by immunohistochemistry and ELISA (see Materials and methods). Cell-surface expression of the S glycoprotein was measured by incubating the
transfected cell monolayers with anti-FLAG antibody at room temperature before permeabilization. For total S glycoprotein detection, cells were fixed and
permeabilized prior to incubation with the anti-FLAG antibody. A ratio between the surface localization and the total expression was calculated and normalized
to the wild-type protein, then set to a percentage of the wild-type. The error bars represent the maximum and minimum surface to total ratios obtained from
three independent experiments, and the bar height represents the average surface to total ratio.
C.M. Petit et al. / Virology 341 (2005) 215–230 221and all the S mutants were detected throughout the
cytoplasm of transfected cells and exhibited similar intra-
cellular distribution patterns (Fig. 6, panels B, D, F, H, J, L).
To determine and compare the endocytotic profiles of wild-
type and S mutant forms, transfected cells were reacted with
the anti-FLAG antibody under live conditions for 12 h at 37
-C and visualized by confocal microscopy. The majority of
the wild-type S detected by the anti-FLAG antibody
appeared to remain on cell surfaces (Fig. 6, panel A). In
contrast, a significant fraction of cell-surface-expressed CL6
and CL7 as well as the T1229, T1238, and T1247 S mutants
appeared to partially endocytose to cytoplasmic compart-
ments (Fig. 6, panels C, E, G, I, K). The CL7 mutant, but
not the other S mutants, appeared to colocalize with the
early endosomal marker EEA-1 (Fig. 6, panel E). The S
mutants CL1, CL2, CL3, CL4, and CL5 remained in plasma
membranes exhibiting profiles similar to that of the S wild-
type glycoprotein (data not shown).
Time-dependent endocytotic profiles of wild-type and
mutant S proteins
A time-dependent endocytosis assay was utilized to
better visualize the endocytotic patterns of the wild-type
and mutant S glycoproteins as well as to exclude the
possibility that the observed plasma membrane accumu-lation of the wild-type S and some of the S mutants was
due to recirculation of endocytosed S to cell surfaces. In
this assay, cell-surface-expressed S was reacted with anti-
FLAG antibody at 4 -C and subsequently, cells were
incubated at 37 -C for different time periods before
processing for confocal microscopy (see Materials and
methods). Generally, these time-dependent endocytosis
studies were in agreement with the results shown in Fig.
6. Specifically, in cells that were not shifted to 37 -C,
referred to as time zero cells, wild-type and mutant spike
were detected exclusively at the surface of the cells (Fig. 7,
panels A1, B1, C1, D1, E1, F1). At 5 and 15 min after the
shift to 37 -C, the wild-type S remained exclusively at the
surface while the other S mutants were detected in
numerous intracellular vesicles dispersed inside the cell
(Fig. 7, panels A2 and A3 compared to panels B2 and B3,
C2 and C3, D2 and D3, E2 and E3, F2 and F3). By 60 min
after the shift to 37 -C, the wild-type S was still localized
exclusively to the surface of the cell (Fig. 7, panel A4),
while the T1229, T1238, CL6, and CL7 S mutants
appeared to be present throughout the cytoplasm of the
cell (Fig. 7, panels B4, C4, E4, F4). The T1247 S mutant
seemed to undergo rapid and complete endocytosis during
the 60 min observation and appeared to localize into
punctuate structures in the cytoplasm of cells unlike the
fairly even cellular distribution of all other S mutants
Fig. 5. Quantitation of the extent of S-mediated cell fusion. The average size of syncytia for each mutant was determined by digitally analyzing the area of
approximately 300 syncytia stained by immunohistochemistry for S glycoprotein expression using the Image Pro Plus 5.0 software package (see Materials and
methods). Error bars shown represent the standard deviations calculated through comparison of the data from each of three experiments.
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D4, E4, and F4).Discussion
The mechanism by which class I fusion proteins such as
the coronavirus S glycoprotein, the hemagglutinin protein
(HA) of influenza virus, the gp41 of human immunodefi-
ciency virus (HIV), the Ebola virus surface glycoprotein
(GP), and the fusion protein (F) of paramyxovirus facilitateTable 1
Grouping of S mutants by their cell-surface expression and cell-fusion
properties
Group Mutants Surface % Fusion %
Control WT 100 100
I T1247 79.15 34.01
CL1 95.26 27.21
CL2 78.17 25.14
CL3 86.25 32.41
CL4 80.12 29.00
CL5 92.33 23.93
CL6 86.81 48.53
II T1229 90.68 78.19
CL7 88.26 85.17
III T1214 23.40 15.52
IV T1238 93.77 143.09membrane fusion during viral entry into cells has been
extensively investigated (Eckert and Kim, 2001; Hernandez
et al., 1996; Tsai et al., 2003; White, 1992; Zelus et al.,
2003). Currently, specific membrane fusion models have
been proposed all of which include the following general
steps: (a) binding of a receptor through a receptor-specific
domain located within the ectodomain of the viral glyco-
protein; (b) induction of a conformational change via low
pH or binding to the receptor that exposes a fusion peptide,
typically a hydrophobic region in the membrane-anchored
subunit, which inserts into the cellular lipid membrane; (c)
formation of a trimer-of-hairpins-like structure by a-helical
peptides, termed heptad repeat segments, via a transient pre-
hairpin intermediate that facilitates the juxtaposition of the
viral and cellular membranes which then leads to fusion of
the viral envelope with cellular membranes (reviewed in
Eckert and Kim, 2001; Hernandez et al., 1996). Although
the most important domains of the class I fusion proteins are
naturally located in their ectodomains, it has been reported
that intracytoplasmic endodomains play an important role in
intracellular transport and virus-induced cell fusion (Bagai
and Lamb, 1996; Bos et al., 1995; Chang et al., 2000; Lontok
et al., 2004; Schwegmann-Wessels et al., 2004; Sergel and
Morrison, 1995; Seth et al., 2003; Tong et al., 2002; Waning
et al., 2004; Yao and Compans, 1995).
In this paper, we show that mutations that alter the HR1
and predicted fusion peptide domains of the SARS-CoV S
Fig. 6. Confocal microscopic visualization of endocytosed and intracellular distribution of SARS-CoV S glycoprotein mutants. Vero cells expressing wild-type
SARS-CoV S glycoprotein [3xFLAG So (WT)] (A and B), CL6 (C and D), CL7 (E and F), T1229 (G and H), T1238 (I and J), and T1247 (K and L) were
processed for confocal microscopy using two different methods in order to assess different properties of the mutants. Endocytosis patterns (A, C, E, G, I, and K)
were visualized by adding anti-FLAG (green) antibody into the media 12 h prior to processing, enabling detection of the mutant protein after endocytosis from
cellular surfaces. Early endosomes were also detected for these panels using a polyclonal anti-early endosomal antigen I antibody (red). For total glycoprotein
detection (B, D, F, H, J, and L), cells were fixed and permeabilized prior to labeling with anti-FLAG (green).
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regions well separated from the HR1, HR2, and predicted
fusion peptide domains drastically affected S-mediated cell
fusion. Importantly, mutagenesis of the S cytoplasmic
domains suggests that the carboxyl terminus of the S
glycoprotein contains multiple but distinct regulatory
domains that may function in virus-induced cell fusion
through different mechanisms.
Functional domains of the S ectodomain
The CL1 cluster mutation is located within the
predicted fusion peptide. The constructed cluster mutations
replaced the amino terminal a and d positions of the
predicted fusion peptide resulting in shortening the
predicted a-helical portion of the fusion peptide. The S
mutant glycoprotein carrying the CL1 mutation was
apparently synthesized in comparable levels to the wild-
type S glycoprotein. As expected, although this mutant S
form was able to be expressed on cell surfaces (95% of
wild-type S levels), its ability to cause cell fusion was
inhibited by more than 70% (Table 1; Group I mutants).
This result confirms that the predicted fusion peptide is
absolutely essential for S-mediated cell fusion, although
the engineered collapse of the predicted region does notsignificantly effect glycoprotein synthesis, processing, and
cell-surface expression.
Recent studies have shown that interactions between
HR1 and HR2 of SARS-CoV are critical in producing the
necessary conformation changes that result in exposure of
the fusion peptide and its insertion into apposed membranes
(Ingallinella et al., 2004; Tripet et al., 2004; Xu et al., 2004).
Biochemical and X-ray crystallography studies have shown
that the HR1 and HR2 form a stable six-helix bundle, in
which the HR1 helices form a central coiled-coil surrounded
by three HR2 helices in an oblique, antiparallel manner
termed the fusion core (Ingallinella et al., 2004; Tripet et al.,
2004; Xu et al., 2004), which is consistent with other class I
fusion proteins (Baker et al., 1999; Bullough et al., 1994;
Caffrey et al., 1998; Chan et al., 1997; Lu et al., 1995; Tan
et al., 1997; Weissenhorn et al., 1998a, 1998b; Weissenhorn
et al., 1997). Amino-acid residues 902–947 in the SARS-
CoV S HR1 domain fold into a predicted 12-turn a-helix
(entire length of the fusion core) with hydrophobic amino
acids predominantly occupying the a and d positions. The
CL3 and CL4 mutations were designed to change the a and
d hydrophobic residues to hydrophilic (lysine) residues.
Both mutant glycoproteins were expressed on cell surfaces
at reduced levels in comparison to the wild-type S gly-
coprotein (14% and 20% reduction, respectively). However,
Fig. 7. Analysis of the endocytotic kinetic profile of the truncation mutants and the acidic cluster mutants using confocal microscopy. After transfection, SARS-
CoV S glycoprotein wild-type [3xFLAG So (WT)] (A1–A4), T1229 (B1–B4), T1238 (C1–C4), T1247 (D1–D4), CL6 (E1–E4), and CL7 (F1–F4)
expressing cells were incubated with an anti-FLAG monoclonal antibody (green) for 1 h and then returned to 37 -C for different times. Early endosomes were
also detected for these panels using a polyclonal anti-early endosomal antigen I antibody (red). Cell nuclei were labeled with To-Pro-3 Iodide (blue). Panels
A1–A4, B1–B4, C1–C4, D1–D4, E1–E4, and F1–F4 correspond to 0-, 5-, 15-, and 60-min incubation times at 37 -C, respectively.
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71%, respectively (Table 1; Group I mutants). Therefore, the
inability of the CL3 and CL4 mutants to cause fusion is
most likely due to ectodomain structural changes involving
the HR1 domain. Inhibition of proper HR1 interaction with
HR2 may be the primary cause of the observed inhibition of
S-mediated cell fusion.
The CL2 and CL5 cluster mutations are located upstream
and downstream of HR1 within a predicted a-helical portion
of the S ectodomain extending from residues 875 to 1014.
Both CL2 and CL5 S mutant forms exhibited reduced S-
mediated cell fusion (75% and 76% reduction in comparison
to the S wild-type, respectively), while they were synthe-
sized and expressed on cell surfaces at levels similar to the S
wild-type (Table 1; Group I mutants). These data suggest
that the inability of these S mutants to cause extensive cell
fusion was mostly due to structural alterations of the
extracellular portion of the S glycoprotein. Furthermore,
these results suggest that a-helical portions of the S
ectodomain that are well separated from HR1 and HR2 or
the predicted fusion peptide are important for S-mediated
cell fusion. It is possible that these mutations affect HR1
interactions with HR2 by inhibiting ectodomain conforma-
tional changes required for their optimal interactions.
Specifically, the CL2 mutation is only 16 amino acids
downstream of the predicted fusion peptide. Therefore, this
mutation may interfere with fusion peptide-associated
functions.
Functional domains of the endodomain of S
The T1247 S mutation deletes 8 amino acids from the
carboxyl terminus of S. This S mutant exhibited a 65%
reduction in cell fusion in comparison to the wild-type S,
while cell-surface expression was reduced by 20% in
comparison to the wild-type S (Table 1; Group I mutants).
Kinetic endocytosis experiments revealed that the T1247 S
mutant also endocytosed much faster than the wild-type S
glycoprotein. Acidic cluster motifs are known to serve as
endocytotic signals (Brideau et al., 1999; Zhu et al., 1996).
The rapid endocytosis of the T1247 S mutant form may be
due to the relocation of the acidic cluster KFDEDDSE
proximal to the carboxyl terminus of the S glycoprotein
after removal of the terminal 8 amino acids resulting in more
efficient endocytosis. Therefore, the inability of the S
mutant form to cause extensive cell fusion may be due
primarily to its rapid endocytosis from cell surfaces. It is
worth noting that a similar deletion of 8 amino acids from
the carboxyl terminus of the MHV S glycoprotein resulted
in enhanced S-mediated cell fusion (Chang et al., 2000). A
comparison of the carboxyl-terminal amino-acid sequences
of these two glycoproteins reveals that the MHV S does not
have a well-defined acidic cluster in the SARS-COV S
homologous location; however, the last three amino acids of
the MHV S are charged residues (HED). Therefore, the
ability of the truncated MHV S to cause more cell fusionmay be due to increased surface retention resulting from a
reduction in endocytosis mediated by these charged
residues. Alternatively, the MHV deletion may cause
structural changes that enhance the MHV S fusogenicity
by destabilizing the overall structure of the glycoprotein.
Stabilization of the carboxyl terminus has been shown to
decrease the fusion activity of the vesicular stomatitis virus
G glycoprotein (Waning et al., 2004); therefore, conversely,
it is possible that destabilization of the carboxyl terminus
may cause an increase in fusion.
Of particular interest is the T1238 truncation which
removed the S carboxyl-terminal acidic domain. This S
mutant glycoprotein exhibited a more than 40% increase in
cell fusion relative to the S wild type, while there was only a
slight decrease in cell-surface expression (Table 1; Group IV
mutants). The fact that the overall levels of S glycoprotein
detected on cell surfaces as well as the endocytosis profile
were not altered suggests that this deletion may enhance
fusion via a structural destabilization of the glycoprotein. In
contrast, changing acidic amino acids of the acidic motif to
alanine residues inhibited cell fusion indicating that the
acidic motif was important for S-mediated cell fusion.
Specifically, the CL6 cluster mutation changed the acidic
residues (DEDDSE) to alanine residues (AAAASA). This
mutant protein, while being efficiently expressed at cellular
surfaces (87% of the wild-type protein), exhibited a 51%
reduction in fusion activity in comparison to the wild type
(Table 1; Group I mutant). The observed reduction in S-
mediated cell fusion suggests that the acidic cluster plays an
important regulatory role in S-mediated cell fusion without
appreciably affecting intracellular transport and cell-surface
expression. This result is in sharp contrast to the T1238
truncation that deleted the acidic cluster and caused
enhanced S-mediated cell fusion. A possible explanation
for these seemingly disparate results is that modifications of
the carboxyl terminus produce differential effects on the
structure and function of the protein by rendering the S
glycoprotein more or less prone to S-mediated fusion.
Alternatively, it is possible that the acidic cluster plays
important roles only in the context of the entire S
glycoprotein by regulating binding to other viral or cellular
proteins that may modify the S fusogenic properties.
The acidic cluster located in the cytoplasmic portion of
the SARS CoV S contains a predicted phosphorylation site
(DEDDSE). To address the role of this predicted phosphor-
ylation site within the acidic cluster, the CL7 cluster
mutation was constructed. The CL7 replaces the serine
residue with an alanine residue within the acidic cluster.
This mutant S protein fused cells extensively (85% of the
wild type) and was expressed on cell surfaces at levels
similar to that of the wild-type S (88% of the wild type)
(Table 1; Group II mutants), suggesting that the potential
phosphorylation site does not play an important role in S-
mediated cell fusion and cell-surface expression. However,
the CL7 mutant appeared to recycle to early endosomes in
contrast to the wild-type S, which remained mostly on cell
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phosphorylation site within the acidic cluster may play a yet
unknown role in S retention at cell surfaces. Conversely,
lack of this signal may cause aberrant endocytosis to early
endosomes. The overall charge of the carboxyl terminus
may also play some role in the structure and function of S.
In this regard, there are additional charged amino acids
dispersed upstream and downstream of the mutated charged
cluster that may play some role in S transport and S-
mediated fusion through electrostatic interactions with other
viral and cellular proteins. Additional alanine scanning
mutations would be needed to resolve their potential
contribution to S functions.
In contrast to the MHV S glycoprotein, in which the
domains overlap, the charged region of the SARS-CoV S
glycoprotein and the two cysteine-rich motifs CRM1 and
CRM2 are separate distinct regions (Figs. 1C and 8). The
T1229 mutation deleted the CRM2 domain, while the
T1214 truncation deleted both CRM1 and CRM2. Deletion
of the CRM2 slightly inhibited surface expression (91% of
the wild type) while reducing fusion activity by 22%
(Table 1; Group II mutants). A similar truncation of the
MHV S glycoprotein produced a comparable effect on cell
fusion (Chang et al., 2000). The 1214 truncation severely
inhibited cell-surface expression by 77%, when compared
to the wild type, while cell-to-cell fusion activity was
reduced by 84% (Table 1; Group III mutant). These results
differ from previously published data on similar trunca-
tions of the MHV S glycoprotein. Specifically, it was
found that the replacement of the entire cysteine-rich
domain with amino-acid sequences derived from the
cytoplasmic terminus of the herpes simplex virus 1
(HSV-1) glycoprotein D (gD) severely inhibited MHV S
glycoprotein function without necessarily affecting cell-
surface expression (Chang et al., 2000; Ye et al., 2004). In
contrast, the SARS-CoV S T1214 mutant glycoprotein
failed to be expressed on cell surfaces explaining the
inability of this glycoprotein to cause cell fusion. These
results suggest that the proximal cysteine residues of the
SARS CoV S play crucial roles in intracellular transport
and cell-surface expression. The discrepancy with the
MHV S carboxyl-terminal replacements may be due to
additional gD sequences that facilitated intracellular trans-
port and cell-surface expression. It is worth noting that
depending on the algorithm used to predict the membrane
spanning domain of S, a few of the cysteine residues may
be included in the membrane spanning region (Chang et
al., 2000; Ye et al., 2004). Therefore, it is possible that
deletion of these cysteine residues may lead to S misincorpo-Fig. 8. Cluster alignment of the carboxyl terminus of the SARS-CoV S and the MH
rich motif in their respective protein. The cysteine residues are bolded. The chargration into membranes, resulting in the apparent transport
defects.
Overall, these results suggest that the S-mediated cell
fusion is regulated by both the ecto- and endodomains,
which play important roles in cell-surface expression.
Furthermore, the data suggest that the 17 carboxyl-terminal
amino-acid residues of S exert a negative regulatory
(repressor) effect on S-mediated cell fusion, while both
the carboxyl-terminal acidic cluster and CRM2 domains
exert secondary regulatory roles in S-mediated cell fusion.
Additional studies are required to elucidate the specific
amino-acid requirements of the S endodomain that can
affect S-mediated cell fusion potentially via a transmem-
brane signal transduction process that leads to destabiliza-
tion of the S ectodomain.Materials and methods
Cells
African green monkey kidney (Vero) cells were obtained
from the American Type Culture Collection (Rockville,
MD). Cells were propagated and maintained in Dulbecco
modified Eagle medium (Sigma Chemical Co., St. Louis,
MO) containing sodium bicarbonate and 15 mM HEPES
supplemented with 10% heat-inactivated fetal bovine serum.
Plasmids
The parental plasmid used in the present study, SARS-S-
Optimized, has been previously described (Li et al., 2003).
The Spike-3XFLAG-N gene construct was generated by
cloning the codon-optimized S gene, without the DNA
sequence coding for the signal peptide, into the p3XFLAG-
CMV-9 plasmid vector (Sigma). PCR overlap extension
(Aiyar et al., 1996) was used to construct the alanine
mutants, cluster mutants, and the single point mutants. In
order to construct the truncation mutants, primers were
designed that incorporated a stop codon and a BamHI
restriction site at the appropriate gene site. Restriction
endonuclease sites HindIII and BamHI were then used
to clone the gene construct into the Spike-3XFLAG-N
plasmid.
The constructed cluster mutants targeting the S
ectodomain changed the following sets of amino acids
to lysine residues: CL:1 Y(855), L(859), G(862); CL2:
L(898), N (901); CL3: L(927), L(930), V(934); CL4:
L(941), L(944); CL5: L(983), L(986). The cluster mutantsV S glycoproteins. The shaded residues indicate the position of the cysteine-
ed clusters are indicated by a bracket over the corresponding regions.
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acids to alanine residues: CL6: D(1239), E(1240),
D(1241), D(1242), E(1244); CL7: S(1243) (Figs. 1B
and C).
Production of SARS-CoV S monoclonal antibodies
The monoclonal antibodies SW-111 was raised against
the Spike envelope glycoprotein of the SARS virus. A
synthetic, codon-optimized gene corresponding to SAR-
CoV S glycoprotein coding sequences (Li et al., 2003) was
engineered to produce truncated, secreted proteins contain-
ing C-terminal His-tags which encode either the entire
ectodomain or just the receptor binding domain of S1. These
genes were cloned into baculoviral vectors, and the resulting
virus was used to infect insect cell lines (High Five)
(Invitrogen, Carlsbad, CA). The supernatants were then
tested by Western blotting using anti-6-His antibodies.
Protein was partially purified from supernatants by passage
through a nickel column and then concentrated by ultra-
filtration. Additional protein derived in an analogous
fashion was provided by the laboratory of Stephen Harrison.
Standard protocols for mouse immunization were used. The
animals were maintained in the animal facility of Dana
Farber Cancer Institute, and hybridomas and monoclonal
antibodies were produced in the Dana Farber/Harvard
Cancer Center Monoclonal Antibody Core. Spleenocytes
from immunogenized mice were fused with NS-1 myeloma
cells (ATCC) using standard protocols. Antibody-producing
clones were identified by Western blot analysis, using
purified SARS-CoV S. The positive cells were then sub-
cloned and re-tested against the purified SARS-CoV S
glycoprotein. Isotype analysis revealed that the antibody
belonged to the IgG-1 class.
Western blot and S oligomerization analysis
Vero cell monolayers in six-well plates were transfected
with the indicated plasmids utilizing the Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s
directions. At 48 h post-transfection, cells were collected by
low-speed centrifugation, washed with Tris-buffered saline
(TBS), and lysed at on ice for 15 min in mammalian protein
extraction reagent supplemented with a cocktail of protease
inhibitors (Invitrogen/Life Technologies). Insoluble cell
debris was pelleted, samples were electrophoretically
separated by SDS-PAGE, transferred to nitrocellulose
membranes, and probed with anti-SARS CoV monoclonal
antibody at a 1:10 dilution. Samples being analyzed for
transport and processing were boiled for 5 min and treated
with beta mercaptoethanol, while samples being analyzed
for trimer formation were not. Subsequently, blots were
incubated for 1 h with a peroxidase-conjugated secondary
antibody at a 1:50,000 dilution and then visualized on X-ray
film by chemiluminescence (Pierce Chemicals, Rockford,
IL). All antibody dilutions and buffer washes wereperformed in TBS supplemented with 0.135 M CaCl2 and
0.11 M MgCl2 (TBS–Ca/Mg).
Cell-surface immunohistochemistry
Vero cell monolayers in six-well plates were trans-
fected with the indicated plasmids utilizing the Lipofect-
amine 2000 reagent (Invitrogen) according to the
manufacturer’s directions. At 48 h post-transfection, the
cells were washed with TBS–Ca/Mg and either fixed with
ice-cold methanol or left unfixed (live). Immunohisto-
chemistry was performed by utilizing the Vector Labo-
ratories Vectastain Elite ABC kit (Vector Laboratories,
Burlingame, CA) essentially as described in the manu-
facturer’s directions. Briefly, cells were washed with
TBS–Ca/Mg and incubated in TBS supplemented with
5% normal horse serum and 5% bovine serum albumin at
room temperature for 1 h. After blocking, cells were
reacted with anti-FLAG antibody (1:500) in TBS blocking
buffer for 3 h, washed four times with TBS–Ca/Mg, and
incubated with biotinylated horse anti-mouse antibody.
Excess antibody was removed by four washes with TBS–
Ca/Mg and subsequently incubated with Vectastain Elite
ABC reagent for 30 min. Finally, cells were washed three
times with TBS–Ca/Mg, and reactions were developed
with NovaRed substrate (Vector Laboratories) according
to the manufacturer’s directions.
Determination of cell-surface to total cell S glycoprotein
expression
Vero cell monolayers in six-well plates were transfected
with the indicated plasmids and processed for immuno-
histochemistry as described above with the exception that
the ABTS Substrate Kit, 2,2V-azino-bis(3-ethylbenzthizo-
line-6-sulfonic acid) (Vector Laboratories) was used
instead of the NovaRed substrate. After the substrate
was allowed to develop for 30 min, 100 Al of the
developed substrate was transferred, in triplicate, to a 96-
well plate. The samples were then analyzed for color
change at a wavelength of 405 nm. The absorbance
reading from cell-surface labeling experiments obtained
from live cells was divided by the total labeled absorbance
readings obtained from fixed cells which were then
normalized to the wild-type protein values. The measure-
ments were then converted to percentages reflecting the
ratio of S present on cell surfaces versus the total S
expressed in the transfected cells.
Confocal microscopy
Vero cell monolayers grown on coverslips in six-well
plates were transfected with the indicated plasmids utiliz-
ing the Lipofectamine 2000 reagent (Invitrogen) according
to the manufacturer’s directions. For the endocytosis
analysis of the mutants, anti-FLAG diluted 1:500 in TBS
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serum albumin (TBS blocking buffer) was added to the cell
culture media for 12 h before processing. At 48 h post-
transfection, cells were washed with TBS and fixed with
electron microscopy-grade 3% paraformaldehyde (Electron
Microscopy Sciences, Fort Washington, PA) for 15 min,
washed twice with TBS–Ca/Mg, and permeabilized with
0.1% Triton X-100. Monolayers were blocked for 1 h with
TBS blocking buffer before incubation for 3 h with anti-
FLAG antibody (Sigma) diluted 1:500 in TBS blocking
buffer. Cells were then washed extensively and subse-
quently incubated for 1 h with Alexafluor 488-conjugated
anti-immunoglobulin G (IgG) (Molecular Probes) diluted
1:750 in TBS blocking buffer. To visualize the early
endosomes, cells were stained with a 1:500 dilution of
anti-early endosomal antigen I antibody (Affinity Biore-
agents Inc.). Cells were examined by using a Leica TCS
SP2 laser-scanning microscope (Leica Microsystems,
Exton, PA) fitted with a 63 Leica objective lens
(Planachromatic; 1.4 numerical aperture). Individual optical
sections in the z axis, averaged eight times, were collected
simultaneously in the different channels at a 512  512
pixel resolution as described previously (Foster et al.,
2004; Lee et al., 2000). Images were compiled and
rendered in Adobe Photoshop.
S glycoprotein endocytosis assay
Vero cell monolayers grown on coverslips in six-well
plates were transfected with the indicated plasmids utilizing
the Lipofectamine 2000 reagent (Invitrogen) according to
the manufacturer’s directions. At 48 h post-transfection, the
cells were washed once with room temperature TBS–Ca/
Mg. The plates were then moved to a 4 -C cold room and
washed with 4 -C TBS–Ca/Mg. The cells were labeled for
1 h at 4 -C with anti-FLAG antibody diluted 1:500 in TBS
blocking buffer. The cells were washed with 4 -C TBS three
times and then brought back to 37 -C and allowed to
incubate for their respective time points. Then, the cells
were immediately fixed and permeabilized with ice-cold
methanol. Monolayers were blocked for 2 h in TBS
blocking buffer before incubation for 1 h with Alexafluor
488-conjugated anti-immunoglobulin G (IgG) (Molecular
Probes) diluted 1:750 in TBS–Ca/Mg blocking buffer. After
incubation, excess antibody was removed by washing five
times with TBS–Ca/Mg. The nuclei were counterstained for
15 min with TO-PRO-3 iodide (1:5000 dilution) and
visualized at 647 nm. Cells were examined by using a
Leica TCS SP2 laser-scanning microscope (Leica Micro-
systems, Exton, Pa.) fitted with a 63 Leica objective lens
(Planachromatic; 1.4 numerical aperature). Individual opti-
cal sections in the z axis, averaged eight times, were
collected simultaneously in the different channels at 512 
512 pixel resolution as described previously (Foster et al.,
2004; Lee et al., 2000). Images were compiled and rendered
in Adobe Photoshop.Quantitation of the extent of S-mediated cell fusion
Vero cell monolayers in six-well plates were transfected
in triplicate with the indicated plasmids utilizing the
Lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s directions. Concurrently, Vero cell mono-
layers in six-well plates were transfected with the plasmid
encoding the ACE2 receptor protein utilizing the Lipofect-
amine 2000 reagent (Invitrogen) according to the manu-
facturer’s directions. At 24 h post-transfection, cells
containing the mutant plasmids, the ACE2 receptor, and
normal untransfected cells were washed with TBS–Ca/
Mg, trypsinized, and overlayed in a single well of a six-
well plate at a ratio of 2 ml (cells transfected with the
ACE2 receptor):0.5 ml (cells transfected with the
mutant):1.5 ml (untransfected cells). All of the cells
transfected with ACE2 were pooled to ensure that every
well had an equal amount of cells with receptor expressed
on their surface. After incubation for 24 h, the cells were
washed with TBS–Ca/Mg and fixed with ice-cold
methanol. Immunohistochemistry was performed by utiliz-
ing the Vector Laboratories Vectastain Elite ABC kit
essentially as described in the manufacturer’s directions.
Briefly, cells were washed with TBS–Ca/Mg and incu-
bated in TBS blocking buffer supplemented with normal
horse serum at room temperature for 1 h. After blocking,
cells were reacted with anti-FLAG antibody (1:500) in
TBS blocking buffer for 3 h, washed four times with
TBS–Ca/Mg, and incubated with biotinylated horse anti-
mouse antibody. Excess antibody was removed by four
washes with TBS–Ca/Mg and subsequently incubated
with Vectastain Elite ABC reagent for 30 min. Finally,
cells were washed three times with TBS–Ca/Mg, and
reactions were developed with NovaRed substrate (Vector
Laboratories) according to the manufacturer’s directions.
The average size of syncytia for each mutant was
determined by analyzing the area of approximately 300
syncytia, from digital images, using the Image Pro Plus
5.0 software package. The averages were then converted to
percentages of the average syncytia size of the wild-type
SARS-CoV S. Error bars shown represent the standard
deviations calculated through comparison of the data from
each of three experiments.Acknowledgments
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